Get the Stockscreener App
2.655
0.56%
0.015
Acumen Pharmaceuticals Inc stock is traded at $2.655, with a volume of 356.17K.
It is up +0.56% in the last 24 hours and up +19.33% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
See More
Previous Close:
$2.67
Open:
$2.66
24h Volume:
356.17K
Relative Volume:
0.79
Market Cap:
$192.73M
Revenue:
-
Net Income/Loss:
$-113.28M
P/E Ratio:
-1.4307
EPS:
-1.8557
Net Cash Flow:
$-105.55M
1W Performance:
+10.49%
1M Performance:
+19.33%
6M Performance:
+9.59%
1Y Performance:
+89.08%
1-Day Range:
$2.62
$2.74
1-Week Range:
$2.39
$2.74
52-Week Range:
$1.21
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.665 | 193.09M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
516.12 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.07 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.31 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.08 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.55 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey
Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026 - TradingKey
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4 - moomoo.com
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Acumen Pharmaceuticals Q2 EPS $(0.45) misses $(0.34) estimate - scanx.trade
Acumen Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position supports pipeline - TradingView
Acumen Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position and pipeline progress - TradingView
Second quarter earnings and operational progress released by Acumen Pharmaceuticals, Inc. - Traders Union
Acumen Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals Reports Q2 Results, Advances Alzheimer’s Programs - TipRanks
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative
Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates - TradingView
Acumen Reports Q2 Net Loss as Alzheimer’s Trial Readout Nears - Quiver Quantitative
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and history - Yahoo Finance Australia
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on August 12. - Moomoo
Enterprise value to EBITDA forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 - manilatimes.net
Alzheimer’s drug developer Acumen sets Aug. 12 webcast at 8 a.m. - Stock Titan
Price to book forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals (ABOS) Holds Steady at $2.24 as Key Support and Resistance Levels Come Into FocusHedge Fund Exposure - dars.gov.et
Acumen Pharmaceuticals (ABOS) Projected to Release Earnings on Tuesday - MarketBeat
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Acumen Pharmaceuticals Inc - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.235|Chg%:+0.105 - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.440|Chg%:+0.160 - TradingKey
Price to earnings forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Enterprise value to revenue forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Income Statement - TradingKey
Acumen Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acumen Pharmaceuticals Inc. (ABOS) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Alzheimer's Candidate AdvancesHigh Estimate Range - dars.gov.et
Acumen Pharmaceuticals Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock SlipsSpecial Dividend Alert - dars.gov.et
Are medical stocks lagging Acumen Pharmaceuticals (ABOS) this year? - MSN
Acumen Pharmaceuticals Presents Enhanced Brain Delivery Program Data and Early Alzheimer?S Disease Insights At Alzheimer?S Association International Conference 2026 - marketscreener.com
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy - Yahoo Finance
Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights - Yahoo Finance
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year? - Yahoo! Finance Canada
Acumen Pharmaceuticals Advances Brain-Delivery Platform With New AAIC 2026 Data - t.co
Acumen Pharmaceuticals Reports Enhanced Brain Penetration of EBD Antibodies and Patient Experience Findings at AAIC 2026 - Quiver Quantitative
38 Early Alzheimer's Participants Describe Memory and Social Challenges - Stock Titan
Acumen Pharmaceuticals (ABOS) Declines 11% as Stock Tests Key Support LevelsALMA Signal - dars.gov.et
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Porter Derrell | Director |
Jun 15 '26 |
Option Exercise |
1.07 |
6,460 |
6,912 |
54,760 |
| Porter Derrell | Director |
Jun 17 '26 |
Sale |
2.33 |
13,040 |
30,318 |
35,500 |
| Porter Derrell | Director |
Jun 16 '26 |
Sale |
2.33 |
12,800 |
29,773 |
35,500 |
| Porter Derrell | Director |
Jun 15 '26 |
Sale |
2.35 |
6,460 |
15,149 |
48,300 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):